In-hospital mortality rates and HIV: A medical ward review, Lilongwe, Malawi

International Journal of STD and AIDS

Volumn 22, Issue 8, 2011, Pages 465-470

  Akinkuotu, A ^a   Roemer, E ^a   Richardson, A ^b   Namarika, D C ^c   Munthali, C ^c   Bahling, A ^c   Hoffman, I F ^a,c   Hosseinipour, M C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

Author keywords

AIDS; HIV; Hospitalization; Inpatient; Malawi; Mortality; Opportunistic infections

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; FEMALE; HIV TEST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; MALE; MEDICAL RECORD REVIEW; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VITAL SIGN; WARD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALAWI; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES;

EID: 79960986894     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011021     Document Type: Article

References (41)

1. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS 2009;4:240-6.
2. Malawi Ministry of Health. Treatment of AIDS: Guidelines for the Use of Antiretroviral Therapy in Malawi. 3rd edn. Lilongwe: Malawi Ministry of Health, 2008.
3. World Health Organization. WHO Country Cooperation Strategy, 2008-2013, Malawi, Second Generation. Geneva: WHO, 2009.
4. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497.
5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853.
6. Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999;13:415.
7. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:5-14.
8. Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001;15:347.
9. Porter K, Babiker A, Bhaskaran K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267.
10. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887.
11. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006;367:1335-42.
12. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782.
13. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. JAIDS J Acquir Immune Defic Syndr 2005;40:336.
14. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006;20:41.
15. Department of HIV and AIDS Ministry of Health. Quarterly Report of the Antiretroviral Treatment Programme in Malawi with Results up to 31st December 2008.
16. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008;371:1603-11.
17. Floyd S, Molesworth A, Dube A, et al. Population-level reduction in adult mortality after extension of free anti-retroviral. PLoS ONE 2010;5:e13499.
18. Lewis DK, Callaghan M, Phiri K, et al. Prevalence and indicators of HIV and AIDS among adults admitted to medical and surgical wards in Blantyre, Malawi. Malawi Med J 2004;14:5.
19. Bardgett H, Dixon M, Beeching N. Increase in hospital mortality from non-communicable disease and HIV-related conditions in Bulawayo, Zimbabwe, between 1992 and 2000. Trop Doct 2006;36:129.
20. Vorster HH, Venter CS, Wissing MP, Margetts BM. The nutrition and health transition in the North West Province of South Africa: a review of the THUSA (Transition and Health during Urbanisation of South Africans) study. Public Health Nutr 2005;8:480-90.
21. BeLue R, Okoror TA, Iwelunmor J, et al. An overview of cardiovascular risk factor burden in sub-Saharan African countries: a socio-cultural perspective. Global Health 2009;5:10.
22. Moses A, Zimba C, Kamanga E, et al. Prevention of mother-to-child transmission: program xchanges and the effect on uptake of the HIVNET 012 regimen in Malawi. AIDS 2008;22:83.
23. McCollum ED, Preidis GA, Kabue MM, et al. Task Shifting Routine Inpatient Pediatric HIV Testing Improves Program Outcomes in Urban Malawi: A Retrospective Observational Study. PloS one 2010;5:e9626.
24. Gea K. Identifying individuals with acute HIV who present to an STI clinic in Lilongwe, Malawi. AIDS 2008 - XVII International AIDS Conference 2008.
25. Chijioke A, Kolo P. Mortality pattern at the adult medical wards of a teaching hospital in sub-Saharan Africa. Int J Trop Med 2009;4:27-31.
26. Reid A, Dedicoat M, Lalloo D, Gilks CF. Trends in adult medical admissions in a rural South African hospital between 1991 and 2002. JAIDS J Acquir Immune Defic Syndr 2005;40:53.
27. Lowrance D, Makombe S, Harries A, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. JAIDS J Acquir Immune Defic Syndr 2007;46:56.
28. Nathanson CA. Sex, illness, and medical care:: A review of data, theory, and method. Soc Sci Med (1967) 1977;11:13-25.
29. Hibbard JH, Pope CR. Another look at sex differences in the use of medical care. Women Health 1986;11:21-36.
30. Bertakis KD, Azari R, Helms LJ, et al. Gender differences in the utilization of health care services. J Fam Pract 2000;49:147-52.
31. Green CA, Pope CR. Gender, psychosocial factors and the use of medical services: a longitudinal analysis. Soc Sci Med 1999;48:1363-72.
32. Banks I. No man's land: men, illness, and the NHS. BMJ 2001;323:1058.
33. Saleri N, Capone S, Pietra V, et al. Outcome and predictive factors of mortality in hospitalized HIV-patients in Burkina Faso. Infection 2009;37:142-7.
34. Chen SCC, Yu JKL, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008;13:513-9.
35. Blount RJ, Davis L, Cattamanchi A, et al. The effect of false positive and false negative microscopy results on mortality among HIV-infected Ugandans undergoing evaluation for TB. Am J Resp Critic Care Med 2010;181:A2257.
36. Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. JAIDS J Acquir Immune Defic Syndr 2008;49:227.
37. Zolopa AR, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4:5575.
38. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697.
39. Murdoch DM, Venter WDF, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008;22:601.
40. *. HIV Med 2010;11:510-8.
41. Kitahata M, Gange S, Moore R. The North American AIDS Cohort Collaboration On ReSearch And Design. Initiating rather than deferring HAART at a CD4 count between 351-500 cells/mm3 is associated with improved survival. Program and abstracts of the 48th ICAAC/46th IDSA:25-8